121 related articles for article (PubMed ID: 10483287)
1. [Controversial aspects regarding metformin in type 2 diabetic patient: reduction of late complications in early, single drug administration; increased risk of death in later administration in combination with sulfonylurea compounds].
Ritzmann P
Praxis (Bern 1994); 1999 Aug; 88(33):1330-1. PubMed ID: 10483287
[No Abstract] [Full Text] [Related]
2. Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study.
Sillars B; Davis WA; Hirsch IB; Davis TM
Diabetes Obes Metab; 2010 Sep; 12(9):757-65. PubMed ID: 20649627
[TBL] [Abstract][Full Text] [Related]
3. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study.
Gulliford M; Latinovic R
Diabetes Metab Res Rev; 2004; 20(3):239-45. PubMed ID: 15133756
[TBL] [Abstract][Full Text] [Related]
4. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy.
Johannes CB; Koro CE; Quinn SG; Cutone JA; Seeger JD
Pharmacoepidemiol Drug Saf; 2007 May; 16(5):504-12. PubMed ID: 17245800
[TBL] [Abstract][Full Text] [Related]
5. Don't throw the baby out with the bath water: mortality with combination metformin and sulfonylurea.
Tayek JA
Diabetes Metab Res Rev; 2007 Feb; 23(2):85-6. PubMed ID: 17262894
[No Abstract] [Full Text] [Related]
6. A comment on 'the risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy'.
Chang Y; Choi NK; Hahn S; Park BJ
Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1072-3; author reply 1073-4. PubMed ID: 17907252
[No Abstract] [Full Text] [Related]
7. [Efficacy and safety of glimepiride plus metformin in a single presentation, as combined therapy, in patients with type 2 diabetes mellitus and secondary failure to glibenclamide, as monotherapy].
González-Ortiz M; Martínez-Abundis E;
Rev Invest Clin; 2004; 56(3):327-33. PubMed ID: 15612515
[TBL] [Abstract][Full Text] [Related]
8. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy.
McAlister FA; Eurich DT; Majumdar SR; Johnson JA
Eur J Heart Fail; 2008 Jul; 10(7):703-8. PubMed ID: 18571471
[TBL] [Abstract][Full Text] [Related]
9. [Sulfonylurea compounds or biguanides in the treatment of type 2 diabetes?].
Mehnert H
Dtsch Med Wochenschr; 1989 Jul; 114(27):1086-8. PubMed ID: 2500320
[No Abstract] [Full Text] [Related]
10. [Oral antidiabetic therapy].
Schneider S; Pazdzierny G; Klein HH
Dtsch Med Wochenschr; 2006 Dec; 131 Suppl 8():S264-7. PubMed ID: 17139584
[TBL] [Abstract][Full Text] [Related]
11. Is metformin safe enough for ageing type 2 diabetic patients?
Gregorio F; Ambrosi F; Filipponi P; Manfrini S; Testa I
Diabetes Metab; 1996 Feb; 22(1):43-50. PubMed ID: 8697295
[TBL] [Abstract][Full Text] [Related]
12. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
[TBL] [Abstract][Full Text] [Related]
13. The UK Prospective Diabetes Study.
Evans M
Lancet; 1998 Dec; 352(9144):1932-3; author reply 1934. PubMed ID: 9863807
[No Abstract] [Full Text] [Related]
14. The UK Prospective Diabetes Study.
Bailey CJ; Grant PJ
Lancet; 1998 Dec; 352(9144):1932; author reply 1934. PubMed ID: 9863806
[No Abstract] [Full Text] [Related]
15. Roundtable. Blueprint for conversion of patients on metformin and sulfonylurea to Glucovance.
Roselli A; Hayes JD; Seidner R; Marchione V; Snyder CM; Mayes K; Stiernberg CM; Milgram L
Manag Care; 2001 Feb; 10(2 Suppl):17-21. PubMed ID: 11729404
[No Abstract] [Full Text] [Related]
16. Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration.
Kahler KH; Rajan M; Rhoads GG; Safford MM; Demissie K; Lu SE; Pogach LM
Diabetes Care; 2007 Jul; 30(7):1689-93. PubMed ID: 17440170
[TBL] [Abstract][Full Text] [Related]
17. Lispro insulin and metformin versus other combination in the diabetes mellitus type 2 management after secondary oral antidiabetic drug failure.
Kokić S; Buković D; Radman M; Capkun V; Gabrić N; Lesko V; Karelović D; Stancerić T
Coll Antropol; 2003 Jun; 27(1):181-7. PubMed ID: 12974145
[TBL] [Abstract][Full Text] [Related]
18. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
Triplitt C; Glass L; Miyazaki Y; Wajcberg E; Gastaldelli A; De Filippis E; Cersosimo E; DeFronzo RA
Diabetes Care; 2006 Nov; 29(11):2371-7. PubMed ID: 17065670
[TBL] [Abstract][Full Text] [Related]
19. [Minor differences in outcome comparing early vs. later initiation of medicamentous blood glucose control in type 2 diabetic patients].
Ritzman P
Praxis (Bern 1994); 1999 Aug; 88(31-32):1289-90. PubMed ID: 10479970
[No Abstract] [Full Text] [Related]
20. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427
[No Abstract] [Full Text] [Related]
[Next] [New Search]
